{"name":"Gossamer Bio","slug":"gossamer","ticker":"GOSS","exchange":"NASDAQ","domain":"gossamerbio.com","description":"Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.","hq":"San Diego, CA","founded":0,"employees":"161","ceo":"Sheila Gujrathi, MD","sector":"Inflammation / Pulmonary","stockPrice":0.33,"stockChange":0,"stockChangePercent":0,"marketCap":"$77M","metrics":{"revenue":48471000,"revenueGrowth":47.1,"grossMargin":100,"rdSpend":0,"netIncome":-170370000,"cash":136932000,"dividendYield":0,"peRatio":-2,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"GB001 patent cliff ($0.0B at risk)","drug":"GB001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Gossamer Bio Announces FDA Fast Track Designation for GB001","summary":"Gossamer Bio announced that the FDA has granted Fast Track designation to GB001 for the treatment of severe asthma.","drugName":"GB001","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Gossamer Bio Reports Third Quarter 2023 Financial Results","summary":"Gossamer Bio reported its third quarter 2023 financial results, with a net loss of $34.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Gossamer Bio Enters into Collaboration Agreement with AstraZeneca","summary":"Gossamer Bio announced a collaboration agreement with AstraZeneca to develop and commercialize GB001 for the treatment of severe asthma.","drugName":"GB001","sentiment":"positive"}],"realNews":[{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-17","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPN3NuRDdLLS1aamZ2dlZfZHN3LTdIY2NYU1pjNEFMMElSa29fbTd1c0pfZDJ4QnFadDBjUzA3YnV0REViZkp5SkZVMkUtdVlWMDF4R3NQM2NGUFVNZE5iTlB0SDlzS1k2WmN3RlI0TFNzT1ozZG84cE9IOVRYNGt1aTR2VUZuM0tMMkMtN3ZBN25OWWc2WGpUMVNWMThkZw?oc=5","date":"2026-03-05","type":"earnings","source":"Finviz","summary":"Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline - Finviz","headline":"Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQemxjQU1oY3lyS2hVSW5XM09jcjhEWWlXQ0FGdjNCWTJObnFRQ1FwbGNQYUNIUXpWVTNnNl9MZTNqRGlzOXhIT2NCeC1OQWpMMVMybDZSOVBVekZEZzhHS2NuTmMxV2dETWpBRVczQUsweng5VGRTOWRKNFZ4eWJwVGcyM0dMWEhCR1RzVUZjRzkzUEN6c1p1MTQ1M29aWEY1cl9MekN2NWw4S3FvSlVURHVyV3I?oc=5","date":"2026-03-05","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Thursday's Intraday Session - Can Fite Biopharma (AMEX:CANF), Gossamer Bi - Benzinga","headline":"12 Health Care Stocks Moving In Thursday's Intraday Session - Can Fite Biopharma (AMEX:CANF), Gossamer Bi","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-24","type":"trial","source":"simplywall.st","summary":"A Look At Gossamer Bio (GOSS) Valuation As PROSERA Phase 3 Seralutinib Results Shape Next Steps - simplywall.st","headline":"A Look At Gossamer Bio (GOSS) Valuation As PROSERA Phase 3 Seralutinib Results Shape Next Steps","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxObk9uOFdKcG01NWhZNVVRVEdVTXZvUnNaY19ONEdKaGJSRmZidzl1ei1JLWR0eEVfeWV1cXR2cGRucmVfV2lhSTU1a2VJRjREZzFnUm5BdjRTQkZOUXdzT1RFQ2h4dXVrdzAwLS1uOHFNMjBRLU80TW5sOHVWeThrbDlZMzdTSGVZdjhWUXJmaUtkVHdJX0ZRQlpSSHlkTjlBWkdfTnVUQjJUMEU1U1Nv?oc=5","date":"2026-02-24","type":"trial","source":"The Pharma Letter","summary":"Gossamer shares plunge after Phase III miss for seralutinib in PAH - The Pharma Letter","headline":"Gossamer shares plunge after Phase III miss for seralutinib in PAH","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxORUZoaEQ5TUY2d2xrTmlxd0dSR2ljUGlUeTZMUUYwZl9vNlZIQUlqT0E5S3l0ODNDbXlLSWY2QkhQZEhUdTYybG5EVGFDUGF6VEFQcmZ2cmU5ZlNNdG9OdUc3WkFJWXdoSGxYTlVvcXM5RUtZb2ZPNzBmZnhSVWE2d0dmaXhaSEh1MnkycWx0QTJvUi1fWktjcER4cWJBY2NIdzhJSA?oc=5","date":"2026-02-24","type":"regulatory","source":"TechStock²","summary":"Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story - TechStock²","headline":"Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPUTRETlNmYmpILVJDNFBVV2hxcTdQaXJZUXpSTXdJdzQzVkQ0eGVNNXc0T2VlNl8tdTZpUHgtYzk2U0RhMUJ6SnFGV2lDaW1DeVlvb1M1NWFPX21rR2E3MGg4clgzU20zeVBYQUZYdDc4MVduQXVibnBYaDI1cDJNTFBlM0NxQjdTbmJSbDJPb3dWblB4b3ZBUklPaEFJMUxRVTBNdW0xUVlBWTNvMWtXMkFMalJ3WDNhUDk3WFBaTlRvWWRfTXNsQUFNOUtjUDlydThkSjVmWk8?oc=5","date":"2026-02-23","type":"trial","source":"Reuters","summary":"Gossamer Bio shares plummet as lung disease drug fails late-stage trial - Reuters","headline":"Gossamer Bio shares plummet as lung disease drug fails late-stage trial","sentiment":"negative"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-16","type":"pipeline","source":"simplywall.st","summary":"Barclays Upgrade and 81% Institutional Ownership Could Be A Game Changer For Gossamer Bio (GOSS) - simplywall.st","headline":"Barclays Upgrade and 81% Institutional Ownership Could Be A Game Changer For Gossamer Bio (GOSS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOTlJQTjBPb1BNZXp3b0NzXzBxNVVGQVVjT2E5RVpScDFrRDJkcGM1aEU5OXVrT1lPS01DZGRCWlo1OHhMZU9hM2pFSEVIdGFwVUgwWTNMd1dkNUU2RDJCNk0tYVBGcW9DY1FFblhsU0RtdXA0d0RIVU9wLWtiY2NaUGhPUWg3TXlyMFE?oc=5","date":"2026-02-06","type":"regulatory","source":"Yahoo Finance","summary":"Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation - Yahoo Finance","headline":"Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-06","type":"regulatory","source":"Insider Monkey","summary":"Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation - Insider Monkey","headline":"Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxONEtlVkpHRjVIb2dPMEdEbUhmTFVUbndyMFp0aHNtZDE2MW9mTTJmdEh3c0N2RkRuaHlNbjh5OWgtWmhOMnJKd0NnYnltLVFyUkxiU2F1S1lNX3pmek1MWWcxbXJseFZlSWstb3NxaXBaTjFtTktoZWFVSWFWZGFHMVRlTTRMWVpNRjd1b2ZNTTdxTVpvekpaTzQ0a0lLTEtjWmxEMUI5SmtObk5DVmdWcDZkdklWb1lQMzZwejVZaWQtSFZiaVQtWDF4d29senBsTGhWWnI2ZTluTl85WXY1NC1JUlQyaTVpbGFr?oc=5","date":"2025-09-25","type":"deal","source":"investingnews.com","summary":"Respira Therapeutics Enters into Agreement with Gossamer Bio Granting Gossamer Option to Acquire Respira from Samsara BioCapital - investingnews.com","headline":"Respira Therapeutics Enters into Agreement with Gossamer Bio Granting Gossamer Option to Acquire Respira from Samsara Bi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPQ0FjUDFSRHJjbWZjQkNUNTN2ZktxWGhVZHZHN3AzcDl3cG41aDhQRlpMaVF3VWtOOFYwWDMyN2t5dXU3U29BYzEwY24tekR6U2NGbDRMTWxSYVRxT0lJMGJxTEtGM3g5ZVV5Y3hiMXFTQUt1V3hoNW9xZVBVaEZQVzBXei1VRmJGeDR5dU5yckdCOVhu?oc=5","date":"2025-09-25","type":"deal","source":"The Pharma Letter","summary":"Gossamer Bio granted option to acquire Respira - The Pharma Letter","headline":"Gossamer Bio granted option to acquire Respira","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1CVUFtVHlWWGhKZlZpZkNuUVdxRmRWODd2aHJ0cmI1WUlUd0xLY2ZPVDZnWThxdnhhQVFYU0Z4LUtuMWxZajdIQUdlU2FuVWJ3ZEo0aUdqc1cwOVNVX3BNSktsbmZaSEZX?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Gossamer Bio (GOSS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Gossamer Bio (GOSS) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"}],"patents":[{"drugName":"GB001","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AstraZeneca","Biogen","Regeneron Pharmaceuticals"],"therapeuticFocus":["Inflammation","Pulmonary"],"financials":{"source":"sec_edgar+yahoo","revenue":48471000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":48471000,"period":"2025-12-31"},{"value":114701000,"period":"2024-12-31"},{"value":114701000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":0,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-170370000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":172249000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":161,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.33,"previousClose":0.33,"fiftyTwoWeekHigh":3.87,"fiftyTwoWeekLow":0.32,"fiftyTwoWeekRange":"0.32 - 3.87","fiftyDayAverage":1.21,"twoHundredDayAverage":2.16,"beta":2.16,"enterpriseValue":143353360,"forwardPE":-2,"priceToBook":-0.63,"priceToSales":1.59,"enterpriseToRevenue":2.96,"enterpriseToEbitda":-0.88,"pegRatio":0,"ebitda":-163228992,"ebitdaMargin":0,"freeCashflow":-93332248,"operatingCashflow":-171266000,"totalDebt":202906000,"debtToEquity":0,"currentRatio":2.64,"returnOnAssets":-41.9,"returnOnEquity":0,"analystRating":"2.6 - Hold","recommendationKey":"hold","numberOfAnalysts":7,"targetMeanPrice":3.69,"targetHighPrice":15,"targetLowPrice":0.3,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.2,"institutionHeldPercent":72.8,"sharesOutstanding":234696281,"floatShares":211156244,"sharesShort":36622286,"shortRatio":1.14,"shortPercentOfFloat":15.6,"epsTrailing":-0.71,"epsForward":-0.17,"revenuePerShare":0.21,"bookValue":-0.53,"officers":[{"age":67,"name":"Mr. Faheem  Hasnain","title":"Co-Founder, CEO, President & Chairman"},{"age":50,"name":"Mr. Bryan  Giraudo","title":"COO & CFO"},{"age":65,"name":"Dr. Richard  Aranda M.D.","title":"Chief Medical Officer"},{"age":58,"name":"Mr. Christian  Waage J.D.","title":"Executive Vice President of Technical Operations & Administration"},{"age":null,"name":"Mr. Jeff  Boerneke","title":"General Counsel & Secretary"},{"age":null,"name":"Ms. Jeanine  Anthony","title":"Senior Vice President of Marketing"},{"age":null,"name":"Ms. Deanna  Weber","title":"Executive Vice President of Human Resources"},{"age":59,"name":"Dr. Robert F. Roscigno Ph.D.","title":"Senior Vice President of Clinical Development of Pulmonary Vascular Disease"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.gossamerbio.com","phone":"858 684 1300"}}